S100A10 and nonpapillary renal cell carcinoma: Another study demonstrated that targeting the PLG receptor S100A10 suppresses angiogenesis in clear cell renal cell carcinoma (ccRCC), proving that PLG inhibition may represent a promising therapeutic strategy to impede tumor progression in ccRCC (Xiao et al., 2019).